USP1 inhibitors detailed in Yantai New Drug Creation patent
May 26, 2026
Yantai New Drug Creation Shandong Laboratory has prepared and tested new heterocyclic amide compounds acting as ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors potentially useful for the treatment of cancer.